2-哌啶-4-基-1,2,3,4-四氢异喹啉 | 200413-62-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 2-哌啶-4-基-1,2,3,4-四氢异喹啉
• 中文别名: 2-哌啶-4-基-1,2,3,4-四氢-异喹啉
• 英文名称: 2-(piperidin-4-yl)-1,2,3,4-tetrahydroisoquinoline
• 英文别名: 2-piperidin-4-yl-3,4-dihydro-1H-isoquinoline
• CAS: 200413-62-3
• 化学式: C₁₄H₂₀N₂
• mdl: MFCD06738859
• 分子量: 216.326
• InChiKey: IKPZUTBWXLFVAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-(4-bromo-phenyl)-5-methanesulfonyl-1-oxiranylmethyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine 、 2-哌啶-4-基-1,2,3,4-四氢异喹啉 以 乙醇 为溶剂， 生成 1-[3-(4-Bromo-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-piperidin-1-yl]-propan-2-ol
  参考文献：
  名称：

  The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors

  摘要：

  A series of competitive, reversible cathepsin S (CatS) inhibitors was investigated. An earlier disclosure detailed the discovery of the 4-(2-keto-1-benzimidazolinyl)-piperidin-1-yl moiety as an effective replacement for the 4-arylpiperazin-1-yl group found in our screening hit. Continued investigation into replacements for the 4-aryl piperazine resulted in the identification of potentially useful CatS inhibitors with enzymatic and Cellular activity similar to that of JNJ 10329670 as disclosed in a previous publication. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.038
• 作为产物：
  描述：

  异喹啉 在 甲醇 、 sodium tetrahydroborate 、 三乙酰氧基硼氢化钠 、 nickel dichloride 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 2-哌啶-4-基-1,2,3,4-四氢异喹啉
  参考文献：
  名称：

  [EN] DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS
  [FR] INDUCTEURS, À BASE DE DIPHÉNYLBUTYLPIPÉRIDINE, DE L'AUTOPHAGIE

  摘要：

  公开号：

  WO2011143444A3

文献信息

• [EN] PRMT5 INHIBITORS<br/>[FR] INHIBITEURS DE PRMT5
  申请人：MERCK SHARP & DOHME

  公开号：WO2021126728A1

  公开（公告）日：2021-06-24

  The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

  本发明提供了一种式（I）的化合物及其药用可接受的盐、酯和前药，这些化合物是PRMT5抑制剂。还提供了制备式I化合物的方法，包括含有式I化合物的药物组合物，以及使用这些化合物治疗癌症、镰状细胞贫血和遗传性胎儿血红蛋白（HPFH）突变的方法。
• Triazolo-pyrimidine derivatives as ligands for gaba receptors
  申请人：——

  公开号：US20030045532A1

  公开（公告）日：2003-03-06

  A class of substituted or 6,7-ring fused [1, 2, 3]triazolo[1,5-&agr;]-pyrimidine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position and an amino moiety at the 5-position, are selective ligands for GABA A receptors, in particular having high affinity for the &agr;2 and/or ◯subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.

  一类取代或6,7-环融合的[1, 2, 3]三唑[1,5-α]-嘧啶衍生物，其在3-位置具有可选的取代环烷基、苯基或杂环烷基取代基，以及在5-位置具有氨基团，是GABAA受体的选择性配体，特别是对其α2和/或χ亚基具有高亲和力，因此对于治疗和/或预防中枢神经系统疾病，包括焦虑和抽搐，具有益处。
• Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity
  作者：Manuel de Lera Ruiz、Junying Zheng、Michael Y. Berlin、Kevin D. McCormick、Robert G. Aslanian、Robert West、Joyce Hwa、Jean Lachowicz、Margaret van Heek

  DOI：10.1016/j.bmcl.2013.08.013

  日期：2013.11

  A novel series of non-imidazole bicyclic and tricyclic histamine H3 receptor antagonists has been discovered. Compound 17 was identified as a centrally penetrant molecule with high receptor occupancy which demonstrates robust oral activity in rodent models of obesity. In addition compound 17 possesses clean CYP and hERG profiles and shows no behavioral changes in the Irwin test.

  已经发现了一系列新的非咪唑双环和三环组胺H 3受体拮抗剂。化合物17被确定为具有高受体占有率的中央渗透分子，在肥胖的啮齿动物模型中显示出强大的口服活性。此外，化合物17具有干净的CYP和hERG谱，在Irwin测试中未显示任何行为变化。
• SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20160318901A1

  公开（公告）日：2016-11-03

  The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

  本申请涉及新颖的取代哌啶基四氢喹啉化合物，以及它们的制备方法，其用于治疗和/或预防疾病，并用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防糖尿病微血管病变、四肢糖尿病溃疡，特别是促进糖尿病足溃疡愈合、糖尿病心力衰竭、糖尿病冠状微血管心脏疾病、周围和心脏血管疾病、血栓栓塞疾病和缺血症、周围循环障碍、雷诺现象、CREST综合征、微循环障碍、间歇性跛行以及周围和自主神经病变的治疗和/或预防。
• SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160304491A1

  公开（公告）日：2016-10-20

  The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

  本申请涉及新型取代哌啶基四氢喹啉，其制备方法，其用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防糖尿病微血管病变、四肢糖尿病溃疡，特别是促进糖尿病足溃疡伤口愈合，糖尿病心力衰竭，糖尿病冠脉微血管心脏疾病，周围和心脏血管疾病，血栓栓塞性疾病和缺血症，周围循环障碍，雷诺现象，CREST综合征，微循环障碍，间歇性跛行以及周围和自主神经病变的治疗和/或预防。